Korean J Gastroenterol.  2014 May;63(5):265-267. 10.4166/kjg.2014.63.5.265.

Is It Necessary for NAFLD Patients to be Screened for Hepatocellular Carcinoma?

• Cheong JY

• KMID: 2155323
• DOI: http://doi.org/10.4166/kjg.2014.63.5.265

Abstract

No abstract available.

MeSH Terms

Carcinoma, Hepatocellular/*diagnosis
Female
Humans
Liver Neoplasms/*diagnosis
Male
Non-alcoholic Fatty Liver Disease/*diagnosis

Reference

References

1. Oh KC, Park SH, Park JC, et al. Is the prevalence of cryptogenic hepatocellular carcinoma increasing in Korea? Korean J Gastroenterol. 2005; 45:45–51.

2. Bhala N, Usherwood T, George J. Non-alcoholic fatty liver disease. BMJ. 2009; 339:b2474.

3. Bhala N, Angulo P, van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology. 2011; 54:1208–1216.

4. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010; 51:1820–1832.

5. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer. 2009; 115:5651–5661.

6. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346:1221–1231.

7. Rim MY, Kwon OS, Ha M, et al. Clinical features of non-alcoholic fatty liver disease in cryptogenic hepatocellular carcinoma. Korean J Gastroenterol. 2014; 63:292–298.

8. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002; 123:134–140.

9. Marrero JA, Fontana RJ, Su GL, et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 2002; 36:1349–1354.

10. Page JM, Harrison SA. NASH and HCC. Clin Liver Dis. 2009; 13:631–647.

11. Sakurai T, Maeda S, Chang L, et al. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci U S A. 2006; 103:10544–10551.

12. Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008; 135:111–121.

13. Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatol. 2012; 56:704–713.

14. Choi SY, Kim D, Kim HJ, et al. The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans. Am J Gastroenterol. 2009; 104:1953–1960.

15. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. Hepatology. 2010; 51:1972–1978.

16. Hashizume H, Sato K, Takagi H, et al. Primary liver cancers with nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2007; 19:827–834.

17. Sanyal A, Poklepovic A, Moyneur E, et al. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin. 2010; 26:2183–2191.

18. Alexander J, Torbenson M, Wu TT, et al. Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study. J Gastroenterol Hepatol. 2013; 28:848–854.

19. Lee JJ, Kwon OS. Occult hepatitis B virus infection and hepatocellular carcinoma. Korean J Gastroenterol. 2013; 62:160–164.

20. Shim J, Kim BH, Kim NH, et al. Clinical features of HBsAg-negative but anti-HBc-positive hepatocellular carcinoma in a hepatitis B virus endemic area. J Gastroenterol Hepatol. 2005; 20:746–751.